SCHEMBL4033582

SCHEMBL4033582

O=C(C(=NO)c1cccc(C(F)(F)F)c1)c1ccncc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.55
BRAF P15056 1/20 0.47
VNN1 O95497 1/20 0.46
TSHR P16473 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALOX15 P16050 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
SRD5A2 P31213 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TLR7 Q9NYK1 1/20 0.43
P2RX1 P51575 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033580 1.00 CES2 (0.55) CES2BRAFVNN1TSHRNPSR1
SCHEMBL4030893 0.85 CES2 (0.77) CES2BRAFVNN1TSHRNPSR1
SCHEMBL4027246 0.84 CES2 (0.54) CES2TSHRNPSR1ALOX15CASP1
SCHEMBL4027250 0.84 CES2 (0.54) CES2TSHRNPSR1ALOX15CASP1
SCHEMBL5967441 0.79 CES2 (0.61) CES2NPSR1LMNAPOLBHPGD
SCHEMBL5967444 0.79 CES2 (0.61) CES2NPSR1LMNAPOLBHPGD
SCHEMBL8920530 0.77 KMT2A (0.57) CES2NPSR1LMNAHPGDL3MBTL1
SCHEMBL6166547 0.77 KMT2A (0.57) CES2NPSR1LMNAHPGDL3MBTL1
SCHEMBL6166550 0.77 KMT2A (0.57) CES2NPSR1LMNAHPGDL3MBTL1
SCHEMBL11002278 0.74 NPSR1 (0.55) CES2NPSR1LMNAPOLBSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP disclosed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP disclosed
US-5717100-A Substituted imidazoles having anti-cancer and cytokine inhibitory activity MERCK & CO., INC. (US) 1998-02-10 US disclosed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO disclosed